A5031308780- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- RNA Interference and Gene Delivery
- T-cell and B-cell Immunology
- Glioma Diagnosis and Treatment
- Cancer Research and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Nanoplatforms for cancer theranostics
- Immune cells in cancer
Northwestern University
2021-2024
Neurological Surgery
2021-2024
University of Chicago
2021
Glioblastoma (GBM) is a highly aggressive and malignant brain tumor with limited therapeutic options poor prognosis. Despite current treatments, the invasive nature of GBM often leads to recurrence. A promising alternative strategy harness potential immune system against cells. Our previous data showed that Bvax (B-cell-based vaccine) can induce responses in preclinical models GBM. In this study, we aim characterize antigenic reactivity BVax-derived antibodies evaluate their potential. We...
Abstract Immunotherapy has revolutionized cancer treatment but yet to be translated into brain tumors. Studies in other solid tumors suggest a central role of B-cell immunity driving immune-checkpoint-blockade efficacy. Using single-cell and single-nuclei transcriptomics human glioblastoma melanoma metastasis, we found that tumor-associated B-cells have high expression checkpoint molecules, known block B-cell-receptor downstream effector function such as plasmablast differentiation...
Abstract Glioblastoma (GBM) presents as a highly aggressive and malignant brain tumor with limited treatment options. Despite the availability of existing therapies, invasive characteristics GBM frequently result in recurrence poor prognosis. We previously developed B-cell-based therapy (BVax) that has shown promising results its ability to induce therapeutic responses preclinical models GBM. Our research revealed potency BVax can be attributed robust antigen-presenting capability, cognate...
Abstract Immunotherapy has revolutionized cancer treatment but yet to be translated into brain tumors. Studies in melanoma and sarcoma, amongst other models, have revealed the accumulation of germinal-center-like B cells as a key survival predictor post-PD1 blockade. We seek leverage cell immunity enhance immunotherapy effectiveness glioblastoma (GBM). In human GBM murine glioma we found that tumor microenvironment (TME) are activated, expression co-inhibitory molecules such CD32 CD72 blocks...